Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
ACIU 
AC Immune Ltd (ACIU)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/09/2026: ACIU (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $8.98
1 Year Target Price $8.98
| 3 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -37.26% | Avg. Invested days 21 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 01/09/2026 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 346.06M USD | Price to earnings Ratio - | 1Y Target Price 8.98 |
Price to earnings Ratio - | 1Y Target Price 8.98 | ||
Volume (30-day avg) 4 | Beta 1.62 | 52 Weeks Range 1.43 - 4.00 | Updated Date 01/9/2026 |
52 Weeks Range 1.43 - 4.00 | Updated Date 01/9/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.9 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1671.89% |
Management Effectiveness
Return on Assets (TTM) -21.97% | Return on Equity (TTM) -74.63% |
Valuation
Trailing PE - | Forward PE 11.24 | Enterprise Value 215957052 | Price to Sales(TTM) 79.15 |
Enterprise Value 215957052 | Price to Sales(TTM) 79.15 | ||
Enterprise Value to Revenue 39.41 | Enterprise Value to EBITDA -0.76 | Shares Outstanding 100600000 | Shares Floating 40064895 |
Shares Outstanding 100600000 | Shares Floating 40064895 | ||
Percent Insiders 38.01 | Percent Institutions 24.82 |
Upturn AI SWOT
AC Immune Ltd
Company Overview
History and Background
AC Immune Ltd. was founded in 2003 as a spin-off from the Swiss Federal Institute of Technology Lausanne (EPFL). The company is a biopharmaceutical company focused on developing therapies for neurodegenerative and neuroinflammatory diseases. Key milestones include its IPO on the NASDAQ in 2014, the advancement of its lead candidates into clinical trials, and strategic partnerships with major pharmaceutical companies.
Core Business Areas
- Neurodegenerative Diseases: Focuses on developing therapies for Alzheimer's disease, Parkinson's disease, and other protein misfolding disorders. This includes small molecules, antibodies, and vaccines targeting specific disease-causing proteins like amyloid-beta, tau, and alpha-synuclein.
- Neuroinflammatory Diseases: Develops treatments for conditions such as multiple sclerosis and amyotrophic lateral sclerosis (ALS), often by targeting inflammatory pathways and immune responses in the central nervous system.
- Prion Diseases: Engages in research and development of treatments for rare but devastating prion diseases, leveraging its expertise in protein misfolding.
Leadership and Structure
AC Immune Ltd. is led by a management team with extensive experience in the biopharmaceutical industry. The company operates under a standard corporate structure, with a board of directors overseeing strategic decisions and an executive team responsible for day-to-day operations. Key leadership roles typically include a Chief Executive Officer (CEO), Chief Medical Officer (CMO), and Chief Financial Officer (CFO).
Top Products and Market Share
Key Offerings
- ACI-35: A therapeutic anti-tau vaccine for Alzheimer's disease currently in clinical development. Competitors include other companies developing tau-targeting therapies such as Eli Lilly and Roche. Market share is currently zero as it is in clinical trials.
- ACI-24: A therapeutic anti-amyloid-beta vaccine for Alzheimer's disease and ARIA (Amyloid-Related Imaging Abnormalities). Competitors include companies developing amyloid-beta targeting therapies like Biogen, Eisai, and Pfizer. Market share is currently zero as it is in clinical trials.
- Crenezumab: An investigational anti-amyloid-beta antibody for Alzheimer's disease, partnered with Genentech (Roche). Its market share is currently zero due to ongoing clinical trials and regulatory review. Competitors include other amyloid-beta antibodies like Lecanemab (Eisai/Biogen).
Market Dynamics
Industry Overview
The biopharmaceutical industry, particularly the neurodegenerative disease sector, is characterized by high research and development costs, long development cycles, significant regulatory hurdles, and intense competition. The market is driven by an aging global population and the increasing prevalence of neurodegenerative diseases, creating a substantial unmet medical need.
Positioning
AC Immune Ltd. is positioned as an innovative biopharmaceutical company with a differentiated approach to targeting proteinopathies and neuroinflammation. Its strengths lie in its proprietary technology platforms, including SupraAntigenu2122 for vaccine development and antibody engineering, and its focus on addressing the root causes of these complex diseases. The company leverages strategic partnerships to advance its pipeline.
Total Addressable Market (TAM)
The total addressable market for neurodegenerative diseases, particularly Alzheimer's, is in the hundreds of billions of dollars globally. AC Immune Ltd. is positioned to capture a significant portion of this market with successful development and commercialization of its pipeline candidates. Its current position is nascent, focusing on building its market share through its drug candidates.
Upturn SWOT Analysis
Strengths
- Proprietary technology platforms (SupraAntigenu2122, antibody engineering).
- Experienced management and scientific team.
- Strong focus on addressing unmet needs in neurodegenerative diseases.
- Strategic partnerships with established pharmaceutical companies.
Weaknesses
- Reliance on clinical trial success, which carries inherent risks.
- Limited product revenue currently, as most candidates are in development.
- The high cost and long timelines associated with drug development.
- Potential dilution from future fundraising activities.
Opportunities
- Growing global demand for effective treatments for Alzheimer's and other neurodegenerative diseases.
- Advancements in understanding disease mechanisms.
- Potential for new drug approvals in a significant unmet medical need area.
- Expansion of partnerships and collaborations.
Threats
- Clinical trial failures or delays.
- Intense competition from other biopharmaceutical companies.
- Stringent regulatory approval processes.
- Changes in healthcare policy and reimbursement landscapes.
- Patent expirations and generic competition for future approved drugs.
Competitors and Market Share
Key Competitors
- Biogen Inc. (BIIB)
- Eli Lilly and Company (LLY)
- Roche Holding AG (RHHBY)
- Pfizer Inc. (PFE)
- AbbVie Inc. (ABBV)
Competitive Landscape
AC Immune Ltd. faces competition from large pharmaceutical companies with significant resources and established market presence, as well as other biotechnology firms developing similar therapies. Its competitive advantages lie in its specific technological platforms and its focus on novel targets and mechanisms of action within the complex field of neurodegenerative diseases.
Growth Trajectory and Initiatives
Historical Growth: Historical growth for AC Immune Ltd. has been characterized by pipeline advancement, strategic partnerships, and equity financing to fund its R&D activities. The company has grown its scientific capabilities and its portfolio of therapeutic candidates.
Future Projections: Future growth projections are contingent on the successful clinical development and commercialization of its lead product candidates. Analyst estimates, if available, would focus on potential peak sales for its late-stage assets and the overall market opportunity.
Recent Initiatives: Recent initiatives likely include progressing its pipeline candidates through clinical trials (e.g., ACI-35, ACI-24), forging new collaborations, and potentially seeking regulatory designations for its investigational therapies.
Summary
AC Immune Ltd. is a promising biopharmaceutical company focused on innovative treatments for neurodegenerative diseases. Its strengths lie in its proprietary technology and experienced team, with significant opportunities in a large and growing market. However, it faces considerable risks due to the inherent challenges of drug development, intense competition, and reliance on clinical trial success. Careful monitoring of its pipeline progression and partnerships is crucial for investors.
Similar Stocks
Sources and Disclaimers
Data Sources:
- AC Immune Ltd. Investor Relations
- SEC Filings (10-K, 10-Q)
- Biopharmaceutical Industry Market Research Reports
- Financial News and Analysis Websites
Disclaimers:
This JSON output is generated for informational purposes only and should not be construed as investment advice. Financial data and market share figures are estimates and subject to change. Users should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About AC Immune Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2016-09-23 | Co-Founder, CEO & Director Dr. Andrea Pfeifer Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 133 | Website https://www.acimmune.com |
Full time employees 133 | Website https://www.acimmune.com | ||
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It develops Crenezumab, a humanized, conformation specific monoclonal antibody used to slow Alzheimer's disease (AD) progression; and Semorinemab, an investigational monoclonal anti Tau antibody that targets the N-terminal portion of the Tau protein and is designed to bind to Tau and slow its spread between neurons for the treatment of AD. The company is also developing ACI-24.060 for the treatment of down syndrome related AD; ACI-7104.056 to treat Parkinson's disease; and ACI-35.030, designs to stimulate a patient's immune system to produce antibodies against pathological phosphorylated Tau. In addition, it develops diagnostic programs consisting of PI-2620, a Tau diagnostic for AD, as well as non-AD Tauopathies; and ACI-12589, a-sync PET tracer that supports the differential diagnosis of multiple system atrophy from other neurodegenerative disease. Further, the company is researching and developing Morphomer Tau aggregation inhibitors to evaluate candidates in AD; Morphomer a-syn to compete with small molecule inhibitors of a-syn aggregation; and NeuroOrphan Tauopathies. Additionally, it generates discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. The company has license agreements and collaborations with Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; and Eli Lilly and Company. AC Immune SA was incorporated in 2003 and is headquartered in Lausanne, Switzerland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.